Navigation Links
Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
Date:2/6/2008

BEIJING, Feb. 6 /Xinhua-PRNewswire-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a pharmaceutical company in the People's Republic of China ("PRC"), today announced that it has achieved significant milestones in the development of isosorbide mononitrate sustained release tablet, a highly effective drug for the prevention and treatment of angina.

Based on extensive clinical trials, isosorbide mononitrate sustained release tablet has shown optimistic results in a study of 1,350 patients with angina who received the drug for over six months. Lotus plans to release the details of the study, and expects to launch the drug pending the approval from SFDA in 2009. Approximately 0.4 to 0.8 million people in China suffer from angina and that figure is anticipated to grow over the coming years due to increases in the aging population. Lotus estimates it will achieve a 10% to 20% market share within two years of launching the drug and a 30% market share within three years.

The drug dilates the blood vessels and lowers the blood pressure. AstraZeneca sells the drug under the trade name Imdur. The components of the drug include matrix tablets, isosorbide mononitrate, and hydroxypropylmethylcellulose (HPMC). Both components are available at low cost and the tablet is easy to manufacture in large scale, which may result in high profit margins for Lotus.

"We have achieved significant milestones for the development of the isosorbide mononitrate sustained release tablet in both pre-clinical trials and manufacturing capabilities," said Dr. Zhongyi Liu, Chairman, CEO and President of Lotus Pharmaceuticals, Inc. "We look forward to introducing this drug, which will diversify the portfolio of our major drugs."

About Lotus Pharmaceuticals, Inc.

Lotus Pharmaceuticals, Inc. ("Lotus") controls and operates Liangfang Pharmaceutical, Ltd. ("Liangfang") and Enze Jiashi Pharmaceutical, Ltd. ("Enze"), two
'/>"/>

SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
2. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
5. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
6. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
7. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
8. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
9. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... PARK CITY, Utah , Sept. 17, 2014 ... into an exclusive global licensing and collaboration agreement ... develop and commercialize NuView,s investigative genomic-based diagnostic biomarker ... The agreement also includes all other future diagnostic-imaging ... compound for in-vivo therapeutic delivery and in-vitro urine ...
(Date:9/17/2014)... Sept. 17, 2014 Cardiac Dimensions ® ... from the TITAN II clinical trial of its ... sustained improvements in mitral regurgitation, functional improvement, quality ... safety and efficacy data, which was consistent with ... 13 at the 26 th annual Transcatheter ...
(Date:9/17/2014)... MILL VALLEY, Calif. , Sept. ... today announced a partnership in the fight against ... the Sarcoma Alliance Suzanne Renee Leider Memorial Assistance ... financial assistance to reimburse sarcoma patients for expenses ... a sarcoma specialist. Scientific literature reinforces the importance ...
Breaking Medicine Technology:NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 3NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 5Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 2Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 3Champions Oncology Partners with Sarcoma Alliance to Bring Personalized Treatment Options to Sarcoma Patients 2Champions Oncology Partners with Sarcoma Alliance to Bring Personalized Treatment Options to Sarcoma Patients 3
... , BOSTON, Nov. 23 AMICAS, Inc. ... management solutions, today announced that it will highlight its enterprise ... America (RSNA) annual meeting from November 29 to December 4 ... in booth #7124. , (Logo: http://www.newscom.com/cgi-bin/prnh/20060202/AMICASLOGO ) ...
... , MINNEAPOLIS, Nov. 23 BridgePoint Medical announced ... for its coronary and peripheral Chronic Total Occlusion (CTO) ... and the Stingray® CTO Re-Entry System. The BridgePoint ... designed to navigate highly diseased arteries in preparation for ...
Cached Medicine Technology:AMICAS' Enterprise Imaging Solutions Highlighted at RSNA 2009 2AMICAS' Enterprise Imaging Solutions Highlighted at RSNA 2009 3BridgePoint Medical(R) Receives European CE Mark for Stingray(R) and CrossBoss(TM) for Opening Completely Blocked Arteries 2BridgePoint Medical(R) Receives European CE Mark for Stingray(R) and CrossBoss(TM) for Opening Completely Blocked Arteries 3
(Date:9/17/2014)... 2014 Promising new research published in ... light on the potential ability of ketones to support ... The study shows that brain hypometabolism ... by impaired glucose uptake and/or utilization, and results suggest ... , The study, by the Research Center on Aging ...
(Date:9/17/2014)... September 16, 2014) A study led by ... the chemotherapy dose threshold below which male childhood ... production. The study appears in September 17 edition ... By clarifying which patients are at highest risk ... the findings to eventually increase use of pre-treatment ...
(Date:9/17/2014)... wine leads to an explosion of flavours in your mouth. ... that can mimic what happens in your mouth when you ... of dryness in the wine. , When wine growers turn ... of processes to bring out the desired flavour in the ... part of the taste is known in wine terminology as ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 A  recent ... of a 24-year-old man named Advait Thakur who had ... caused by degenerative disc disease. This disease led to ... his nerve roots and causing severe pain. Leading spine ... and how it can lead to such severe pain, ...
(Date:9/17/2014)... NetDimensions (AIM: NETD; OTCQX: NETDY), a global ... the opening of the 2014 Next Steps user conference ... very excited to meet up in Chicago again this ... Steps from our clients and partners, which shows how ... look forward to some very engaging and fun days ...
Breaking Medicine News(10 mins):Health News:Journal of Alzheimer's Disease Publishes New Study Suggesting Ketones have Potential to Compensate for Brain Energy Deficit 2Health News:Journal of Alzheimer's Disease Publishes New Study Suggesting Ketones have Potential to Compensate for Brain Energy Deficit 3Health News:Improved risk identification will aid fertility preservation in young male cancer patients 2Health News:Improved risk identification will aid fertility preservation in young male cancer patients 3Health News:Nanoscience makes your wine better 2Health News:Nanoscience makes your wine better 3Health News:24-Year-Old Back in College After Degenerative Disc Disease Kept Him Out 2Health News:24-Year-Old Back in College After Degenerative Disc Disease Kept Him Out 3Health News:NetDimensions Next Steps User Conference in North America Opens Today with Record Attendance 2Health News:NetDimensions Next Steps User Conference in North America Opens Today with Record Attendance 3
... By Steven Reinberg HealthDay Reporter , THURSDAY, Sept. ... phone use and texting soared in the space of three ... Texting alone caused more than 16,000 deaths in car accidents ... involving cell phones and texting while driving rose 28 percent ...
... S. Bloomberg Faculty of Nursing professor, Dr. Diane Doran, ... will help protect the safety of over 900,000 Canadians ... day. The Canadian Patient Safety Institute and its ... research competition drawing some of Canada,s leading healthcare researchers. ...
... Reporter , THURSDAY, Sept. 23 (HealthDay News) -- It was ... dream. He,d just been plucked from his life as ... the National Basketball Association,s Dallas Mavericks, summer training camp after ... But a small on-court collision with another player led to ...
... to boost research on women,s health over the last two ... among women due to cardiovascular disease, breast cancer, and cervical ... The effort has yielded less but still significant progress ... women, added the committee that wrote the report. ...
... pathology at the University of California, San Diego School ... the Moores UCSD Cancer Center, has been named the ... bestowed by the Metastasis Research Society, an international, non-profit ... was honored at a recent joint meeting of the ...
... and Tallinn, Estonia (September 23, 2010) At an international ... Global TB Vaccine Foundation announced it will initiate a clinical ... led by researchers at Saint Louis University in St. Louis, ... Global Forum on TB Vaccine Development. Building on ...
Cached Medicine News:Health News:Texting Taking a Deadly Toll on Roads 2Health News:Texting Taking a Deadly Toll on Roads 3Health News:$1 million awarded to Bloomberg Faculty of Nursing-led research team 2Health News:Experimental Leukemia Drug Proves a Slam Dunk 2Health News:Experimental Leukemia Drug Proves a Slam Dunk 3Health News:Experimental Leukemia Drug Proves a Slam Dunk 4Health News:Increased attention to women's health research has yielded gains on some important conditions, but progress lags on others 2Health News:Increased attention to women's health research has yielded gains on some important conditions, but progress lags on others 3Health News:David Cheresh receives top award for cancer metastasis research 2Health News:New TB vaccine enters clinical testing 2
Bipolar gingivoplasty loop. Individual sterile packs....
The Hilan pneumatic high speed drill system consists of a pneumatic motor and drill with various cutting attachments....
The XK-95 High Speed Drill System sets new technological and performance standards for surgical drill systems....
Circular Spine Retractor System for microsurgical interventions in the lumbar and cervical spine region. The system has been approved in over 120 cases....
Medicine Products: